Missing the Covid boat, Junshi stumbles back to old business
Despite developing an oral drug to treat Covid, the biotech company's revenue fell sharply and its net loss widened by nearly 40% in the first quarter Key Takeaways: Junshi Bioscience's…
Recent Articles
Missing the Covid boat, Junshi stumbles back to old business
1877.HK
688180.SHG
RELATED ARTICLES
-
Junshi hopes new scientist CEO can cure its woes
1877.HK 688180.SHG -
Junshi narrows its losses but delivers no cure for share price woes
1877.HK 688180.SHG
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
1672.HK
-
Everest reaches new heights on growing drug sales
1952.HK
